170 related articles for article (PubMed ID: 32601264)
21. Clinicopathologic analysis of low-stage sporadic ovarian carcinomas: a reappraisal.
Karamurzin Y; Leitao MM; Soslow RA
Am J Surg Pathol; 2013 Mar; 37(3):356-67. PubMed ID: 23282975
[TBL] [Abstract][Full Text] [Related]
22. p53 Expression in Luminal Breast Cancer Correlates With TP53 Mutation and Primary Endocrine Resistance.
Mueller S; Grote I; Bartels S; Kandt L; Christgen H; Lehmann U; Gluz O; Graeser M; Kates R; Harbeck N; Kreipe H; Christgen M
Mod Pathol; 2023 Apr; 36(4):100100. PubMed ID: 36788081
[TBL] [Abstract][Full Text] [Related]
23. The prognostic value of TP53 mutations in hypopharyngeal squamous cell carcinoma.
Omura G; Ando M; Ebihara Y; Saito Y; Kobayashi K; Fukuoka O; Akashi K; Yoshida M; Asakage T; Yamasoba T
BMC Cancer; 2017 Dec; 17(1):898. PubMed ID: 29282038
[TBL] [Abstract][Full Text] [Related]
24. A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients.
Alsner J; Jensen V; Kyndi M; Offersen BV; Vu P; Børresen-Dale AL; Overgaard J
Acta Oncol; 2008; 47(4):600-7. PubMed ID: 18465328
[TBL] [Abstract][Full Text] [Related]
25. Correlation of p53 immunohistochemistry with TP53 mutational status and overall survival in newly diagnosed acute myeloid leukaemia.
Fitzpatrick MJ; Boiocchi L; Fathi AT; Brunner AM; Hasserjian RP; Nardi V
Histopathology; 2022 Oct; 81(4):496-510. PubMed ID: 35869818
[TBL] [Abstract][Full Text] [Related]
26. Accurate interpretation of p53 immunohistochemical patterns is a surrogate biomarker for TP53 alterations in large B-cell lymphoma.
Li X; Luo D; Zhang L; Li Q; Fan J; Zhang J; Huang B; Yang M; Nie X; Chang X; Pan H
BMC Cancer; 2023 Oct; 23(1):1008. PubMed ID: 37858047
[TBL] [Abstract][Full Text] [Related]
27. The High Expression of p53 Is Predictive of Poor Survival Rather
Jin Y; Zhao X; Song X; Wang R; Fan Z; Wang P; Yang M; Zhou F; Bao Q; Wang L
J Oncol; 2023; 2023():3801526. PubMed ID: 36660245
[No Abstract] [Full Text] [Related]
28. Pattern of nucleotide variants of TP53 and their correlation with the expression of p53 and its downstream proteins in a Sri Lankan cohort of breast and colorectal cancer patients.
Manoharan V; Karunanayake EH; Tennekoon KH; De Silva S; Imthikab AIA; De Silva K; Angunawela P; Vishwakula S; Lunec J
BMC Cancer; 2020 Jan; 20(1):72. PubMed ID: 32000721
[TBL] [Abstract][Full Text] [Related]
29.
Na K; Sung JY; Kim HS
Anticancer Res; 2017 Dec; 37(12):6697-6703. PubMed ID: 29187446
[TBL] [Abstract][Full Text] [Related]
30. Prognostic significance of CD117 expression and
Luo Y; Huang W; Zhang H; Liu G
Oncol Lett; 2018 May; 15(5):6161-6170. PubMed ID: 29616097
[TBL] [Abstract][Full Text] [Related]
31. Accuracy of bone marrow histochemical TP53 expression compared to the detection of TP53 somatic mutations in patients with myelodysplastic syndromes harbouring a del5q cytogenetic abnormality.
Oliva EN; Latagliata R; Sabattini E; Mammì C; Cuzzola M; D'Errigo MG; Cannatà MC; Bova I; Capodanno I; Palumbo GA; Pane F; Reda G; Fianchi L; Riva M; Poloni A
Am J Blood Res; 2021; 11(4):417-426. PubMed ID: 34540351
[TBL] [Abstract][Full Text] [Related]
32. Immunohistochemical correlates of TP53 somatic mutations in cancer.
Murnyák B; Hortobágyi T
Oncotarget; 2016 Oct; 7(40):64910-64920. PubMed ID: 27626311
[TBL] [Abstract][Full Text] [Related]
33. Mutation spectrum of TP53 gene predicts clinicopathological features and survival of gastric cancer.
Tahara T; Shibata T; Okamoto Y; Yamazaki J; Kawamura T; Horiguchi N; Okubo M; Nakano N; Ishizuka T; Nagasaka M; Nakagawa Y; Ohmiya N
Oncotarget; 2016 Jul; 7(27):42252-60. PubMed ID: 27323394
[TBL] [Abstract][Full Text] [Related]
34. Correlation of genetic and immunodetection of TP53 mutations in malignant and benign prostate tissues.
Wertz IE; Deitch AD; Gumerlock PH; Gandour-Edwards R; Chi SG; de Vere White RW
Hum Pathol; 1996 Jun; 27(6):573-80. PubMed ID: 8666367
[TBL] [Abstract][Full Text] [Related]
35. p53 and Ki-ras as prognostic factors for Dukes' stage B colorectal cancer.
Bouzourene H; Gervaz P; Cerottini JP; Benhattar J; Chaubert P; Saraga E; Pampallona S; Bosman FT; Givel JC
Eur J Cancer; 2000 May; 36(8):1008-15. PubMed ID: 10885605
[TBL] [Abstract][Full Text] [Related]
36. The predictive capability of immunohistochemistry and DNA sequencing for determining
Roshandel AK; Busch CM; Mullekom JV; Cuoco JA; Rogers CM; Apfel LS; Marvin EA; Sontheimer HW; Umans RA
Oncotarget; 2019 Oct; 10(58):6204-6218. PubMed ID: 31692772
[TBL] [Abstract][Full Text] [Related]
37. Significance of TP53 mutations determined by next-generation "deep" sequencing in prognosis of estrogen receptor-positive breast cancer.
Uji K; Naoi Y; Kagara N; Shimoda M; Shimomura A; Maruyama N; Shimazu K; Kim SJ; Noguchi S
Cancer Lett; 2014 Jan; 342(1):19-26. PubMed ID: 23973262
[TBL] [Abstract][Full Text] [Related]
38. Maspin subcellular expression in wild-type and mutant
Gurzu S; Jung I; Sugimura H; Stefan-van Staden RI; Yamada H; Natsume H; Iwashita Y; Szodorai R; Szederjesi J
World J Gastrointest Oncol; 2020 Jul; 12(7):741-755. PubMed ID: 32864042
[TBL] [Abstract][Full Text] [Related]
39.
Yu R; Sun T; Zhang X; Li Z; Xu Y; Liu K; Shi Y; Wu X; Shao Y; Kong L
Onco Targets Ther; 2021; 14():4967-4978. PubMed ID: 34629881
[TBL] [Abstract][Full Text] [Related]
40. P53 in Penile Squamous Cell Carcinoma: A Pattern-Based Immunohistochemical Framework with Molecular Correlation.
Trias I; Saco A; Marimon L; López Del Campo R; Manzotti C; Ordi O; Del Pino M; Pérez FM; Vega N; Alós S; Martínez A; Rodriguez-Carunchio L; Reig O; Jares P; Teixido C; Ajami T; Corral-Molina JM; Algaba F; Ribal MJ; Ribera-Cortada I; Rakislova N
Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345055
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]